Study Design. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistological analysis of spinal cord and pain behavior analysis in a rat neuropathic pain model were conducted to examine the function of microglial basic fibroblast growth factor (bFGF) in the development of neuropathic pain. Objective. To investigate the role of bFGF in spinal microglia during the development of allodynia following spinal nerve ligation in rats. Summary of Background Data. Evidence suggests that the production of bFGF by spinal cord glial cells is increased in response to peripheral nerve injury. Although an association between bFGF and astrocytes has been widely reported, the relationship between bFGF and microglia, particularly with respect to the development of neuropathic pain, remains poorly understood. Methods. Spinal nerve ligation rats were used. After surgery, bFGF expression in the spinal cord was investigated using RT-PCR and immunohistochemistry. Neutralizing antibodies to bFGF were injected intrathecally into rats after spinal nerve ligaton. Spinal cords were used for RT-PCR analysis and pain behavior was analyzed using the von Frey test.
N europathic pain results from damage to the peripheral or central nervous system (CNS) and can appear in the form of hyperalgesia, allodynia, and spontaneous pain, which are often intractable and resistant to treatment. 1 Neuropathic pain is transmitted through neural pathways from the dorsal root ganglion to the spinal cord and ultimately the thalamus. In this pathway, glial cells, such as astrocytes and microglia, in the CNS are involved in the initiation and maintenance of neuropathic pain. 2 The activation of spinal microglia following peripheral nerve injury may also lead to the development of neuropathic pain. Microglia and related signaling molecules may therefore be suitable therapeutic targets for pain control; however, the factors that mediate microglial activity remain unclear.
Basic fibroblast growth factor (bFGF) belongs to a 22-member family of polypeptide growth factors that bind heparin and heparan sulfate proteoglycans. 3 A recent study reported that the expression of bFGF is upregulated in spinal From the cord astrocytes 3 weeks after rat spinal nerve ligation (SpNL). 4 The same research group also demonstrated that the intrathecal injection of bFGF neutralizing antibody attenuates glial fibrillary acidic protein expression and mechanical allodynia at 3 weeks, and suggested that bFGF contributes to the maintenance of allodynia through the activation of astrocytes 5 ; however, microglia appear to be the first cells to respond to nerve injury, as they are activated as early as 4 hours after nerve injury. 6 In vitro studies also showed that microglia release and respond to bFGF, which induces ramified microglial cells to transform into an amoeboid phagocytic cell type; however, it is unknown whether microglia release and respond to bFGF and contribute to the acute phase of allodynia.
Activated microglia induce inflammatory states through the release of inflammatory cytokines, such as interleukin1-b, interferon-g, and tumor necrosis factor-a (TNFa), and the oxidant-generating enzyme myeloperoxidase (MPO). 7 These inflammatory factors have been implicated in the development of degenerative nerve diseases and pain after injury of the nervous system. The regulation of these inflammatory factors by bFGF during the development of allodynia is not well understood. We therefore hypothesized that bFGF plays a critical role in the development of neuropathic pain by stimulating the release of inflammatory factors from microglia.
In the present study, we investigated the role of bFGF in spinal microglia during the development of allodynia after SpNL in rats. Specifically, the effects of a neutralizing antibody to bFGF on the activation of microglia and the acute phase of allodynia development were examined.
MATERIALS AND METHODS

Rat Nerve Injury Model
All animal experimental procedures were performed with the approval of and in accordance with the guidelines of the animal ethics committee of Kitasato University. Six-week-old male Sprague Dawley rats (190-240 g) were used in this study and were housed in a semibarrier system with a controlled environment (23 AE 2 8C, 55 AE 10% humidity, 12-hour light-dark cycle) throughout the study. All rats were fed a diet of standard rodent chow. Rats were anesthetized and their L5 spinal nerves were ligated using a previously described procedure. 8 Briefly, the left L6 transverse processes of rats were removed and left spinal nerves were exposed at L5. L5 nerve injury was induced by tightly ligating the exposed nerves with 6-0 silk. Each layer of muscle and skin was then closed.
bFGF Expression Analysis
For the analysis of bFGF mRNA expression, 48 rats were divided into eight groups of six rats. Rats were anesthetized and the lumbar spinal cord was immediately removed before (untreated rats), and 6, 12, 24 hours, 3, 7, 14, and 28 days after performing the SpNL procedure (n ¼ 6, each time point).
Total RNA was isolated from the spinal cord tissue using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. First-strand cDNA synthesis was performed using Superscript III (Invitrogen) with total RNA as the template. Quantitative RT-PCR was then conducted with obtained cDNA using gene-specific rat primers ( Table 1 ). The MPO and ionized calcium-binding adaptor molecule 1 (Iba1) primers were designed using Primer Blast software (National Center for Biotechnology Information, Bethesda, MD). Melt curve analysis was performed to confirm the specificity of the amplified products. Other primers were designed based on primer sequences reported in the literature. 9 All primers were purchased from Hokkaido System Science Co., Ltd. (Sapporo, Japan). The PCR reaction mixture consisted of 2 mL cDNA, the specific primer set (0.2 mM final concentration), and 12.5 mL SYBR Premix Ex Taq (Takara, Kyoto, Japan) in a final volume of 25 mL. Quantitative PCR was performed using a Real-Time PCR Detection System (CFX-96; Bio-Rad, CA). The PCR cycle parameters consisted of an initial denaturation step at 95 8C for 1 minute, followed by 40 cycles of 95 8C for 5 seconds, and 608C for 30 seconds. mRNA expression was normalized to the levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. The bFGF gene expression levels were compared with untreated rats (treated rats/untreated rats).
Behavioral Tests
Mechanical withdrawal thresholds were assessed using von Frey filaments to estimate mechanical allodynia of the left hind paw. The up-and-down method of testing was used.
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All individuals performing the behavioral testing were blinded to the treatments. After the SpNL procedure, 12 rats were divided into two groups of six rats. One group [SpNL þ antibody (Ab) group] was injected intrathecally using a Hamilton syringe (Hamilton, Reno, NV) with neutralizing antibodies to bFGF (Sigma, St. Louis, MO), and a second group was treated in the same manner with phosphate buffered saline (PBS) (SpNL group). The transcutaneous injections were made into the intravertebral space between the spinal processes of the L5 and L6 vertebra under fluoroscopic guidance (OEC9600, GE OEC Medical Systems, Salt Lake City, UT). A sudden lateral movement of the tail upon the needle entering the subarachnoidal space, as reported by Mestre et al 11 was used as an indicator of successful puncture. For each injection, 50 mg rabbit antibFGF neutralizing antibody in 40 mL PBS was used. The injection volume was determined based on that used in previous studies in which antibodies were injected into the spinal cord. 5 The bFGF concentration was determined based on the findings of our pilot study examining the effects of bFGF on allodynia. The antibody injections were conducted under anesthesia twice a week (just after the SpNL procedure, and 3, 7, 10, 14, 17, 21, 24, and 28 days after ligation). The response to a mechanical stimulus was measured before and 1, 3, 5, 14, and 28 days after the SpNL surgery, before performing the injections (n ¼ 6).
Effect of bFGF Neutralization on Expression of Activated Microglial Markers
To examine changes in glial cells and in the levels of inflammatory factors in the spinal cord, the gene expression of microglia (Iba1) and activated microglia markers (TNFa, interleukin-6, and MPO) was analyzed by RT-PCR for the untreated group and 1 and 3 days after the injection of bFGF neutralizing antibodies in the SpNL and SpNL þ Ab group (n ¼ 6, each time point).
Immunohistochemistry
To investigate the expression of bFGF in microglia and the effect of bFGF neutralizing antibodies on allodynia, immunohistochemistry was performed. One and 3 days after the SpNL surgery, six rats were anesthetized and perfused transcardially with 4% paraformaldehyde in PBS. Six untreated rats were also used as a control group. The lumbar enlargement of the spinal cord was resected, and the collected specimens were immersed in the paraformaldehyde fixative for 20 hours at 4 8C and were then transferred to a 20% sucrose solution in PBS. After further incubation for 20 hours at 4 8C, the tissues were embedded in optimal cutting temperature (OCT) compound (Tissue Tek, Sakura Finetechnical Co., Ltd., Tokyo, Japan) and stored at À80 8C until transverse sections (20-mm thickness) were prepared on a cryostat. The sections were mounted on Superfrost/Plus microscope slides (Fisher Scientific, Hampton, NH), washed three times with PBS, and nonspecific binding sites were then blocked with 1% skim milk in PBS (blocking buffer). Immunohistochemistry was investigated using the following primary antibodies: rabbit anti-bFGF (1:500; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-MPO (1:
Statistical Analyses
All statistical analyses were performed using SPSS software (version 11.0; SPSS Inc., Chicago, IL). A one-way analysis of variance with Fisher least significant difference test was used to determine differences between the untreated and SpNL groups. The nonparametric Mann-Whitney U test or Kruskal-Wallis test was performed following Levene test for equality of variance, with a P value of < 0.05 considered statistically significant. The parametric Fisher least significant difference test was done following Levene test for equality of variance with P ! 0.05. A Kruskal-Wallis test was used to determine differences between the untreated and SpNL or SpNL þ Ab groups. A Mann-Whitney U test was used to determine differences between the SpNL and SpNL þ Ab groups at the same time point. P < 0.05 was considered statistically significant.
RESULTS bFGF Expression and Localization Analysis after SpNL
Quantitative RT-PCR conducted on spinal cord samples from rats in the SpNL group showed that bFGF mRNA was increased significantly 6 hours after SpNL surgery (P < 0.05, Figure 1 ). Elevation of bFGF mRNA was also observed 14 and 28 days after SpNL surgery. Immunohistochemistry analysis of spinal cord sections from rats showed that bFGF (immunoreactivity [IR]) was weak and co-localized with Iba1 IR, in the absence of SpNL (Figure 2A ) One day after SpNL, bFGF IR was strong and co-localized with Iba1 IR in the dorsal horn ( Figure 2B ).
Effect of bFGF Neutralization on Allodynia
Rats in the SpNL group displayed significant mechanical allodynia 1 day after surgery compared with rats in the untreated group (P < 0.05, Figure 3) . Notably, the allodynia persisted for up to 28 days after the SpNL surgery. The withdrawal threshold level in the SpNL þ Ab group was significantly increased compared with the SpNL group from days 1 to 14 after surgery (P < 0.05); however, the development of mechanical allodynia was also observed in the SpNL þ Ab group at day 1 and persisted for up to 28 days after the SpNL surgery.
Effect of bFGF Neutralization on Microglial-Related Markers and Inflammatory Factors
Expression of mRNA for the microglial-related markers Iba1 was increased within 3 days of SpNL compared with the untreated control group (P < 0.05, Figure 4) . Expression of Iba1 mRNA was also detected after SpNL, but was not inhibited by anti-bFGF treatment. Microglial-activated release of cytokines, including TNFa on day 1 and IL6 on day 3, was increased after SpNL compared with the untreated control group (P < 0.05); however, no significant decrease in these cytokines was observed in rats from the SpNL þ Ab group. The expression of MPO mRNA in rats from the SpNL group significantly increased after SpNL surgery (P < 0.05), and the maximum expression of MPO was detected 3 days after surgery. Anti-bFGF treatment significantly inhibited the expression of MPO mRNA during the first 3 days after SpNL surgery (P < 0.05).
Immunolocalization of MPO
Quantitative PCR analysis indicated that MPO mRNA expression increased following SpNL surgery and was decreased by bFGF neutralization. To analyze microglial MPO protein expression, double immunofluorescence staining was performed. In the spinal cords of untreated rats, Iba1 and MPO IR were detected at the edge of the dorsal horn ( Figure 5A , B) and were found to be co-localized ( Figure 5C ). One day after SpNL, Iba IR was observed in the ipsilateral dorsal horn ( Figure 5D ) and was also colocalized with MPO IR (Figure 5E ) in the spinal cord of rats from the SpNL group ( Figure 5F ). The accumulation of Iba IR was also observed in the SpNL þ Ab group at 1 day after SpNL ( Figure 5G) ; however, the number of MPO/Iba IR double-positive regions had decreased in this group ( Figure 5H, I ). At 3 days after SpNL, Iba1 IR had increased in the spinal cord of rats in both the SpNL ( Figure 5J ) and SpNL þ Ab groups ( Figure 5M ), a finding that is consistent with the RT-PCR analysis. MPO IR had also increased 3 days after SpNL in the SpNL group ( Figure 5K, L) ; however, MPO IR was suppressed by bFGF neutralization, again consistent with the RT-PCR analysis ( Figure 5N, O) .
DISCUSSION
In the present study, we found that expression of bFGF mRNA was rapidly increased in the spinal cord during the development of allodynia following spinal nerve injury. Expression of bFGF IR was observed in accumulated microglia, and neutralization of bFGF by intrathecally injected anti-bFGF antibodies inhibited the development of allodynia. In addition, we detected MPO IR in microglia after SpNL, but demonstrated that MPO expression was suppressed by antibody-mediated neutralization of bFGF, suggesting that spinal bFGF activates microglia and contributes to the development of allodynia.
Previous studies have demonstrated that bFGF participates in allodynia development through the activation of astrocytes. 4, 5 The intrathecal infusion of bFGF elevates glial fibrillary acidic protein expression in the spinal cord and induces pain hypersensitivity that persists for 1 week. 12 In Figure 4 . Effects of SpNL and bFGF neutralization on spinal cord cell markers and release of inflammatory factors in the spinal cord. Values are reported as the fold increase in mRNA levels compared with untreated controls. In the SpNL group, MPO mRNA levels increased for the first 3 days after surgery (P < 0.05). In the SpNL þ Ab group, MPO mRNA was inhibited. Data are presented as the mean AE SE. (n ¼ 6). A, mRNA significantly increased on postoperative days 1 or 3 in comparison with the untreated controls (P < 0.05). B, In the SpNL group, the mRNA levels significantly increased in comparison with the SpNL þ Ab group (P < 0.05). bFGF, basic fibroblast growth factor; MPO, myeloperoxidase; SE, standard error; SpNL, spinal nerve ligation. addition, the overexpression of bFGF by the spinal injection of bFGF-encoded adenovirus was shown to induce the gradual recovery of nociceptive function. 13 bFGF levels are also reported to increase in reactive astrocytes of the ipsilateral dorsal horn during the first 3 weeks after SpNL. 4 Consistent with this finding, we also confirmed the elevation of bFGF at 4 weeks after SpNL, suggesting that bFGF also plays an important role in the maintenance of allodynia. We also found that bFGF mRNA in the spinal cord was increased 6 hours after SpNL, but before the development of allodynia. In the spinal cords from nontreated control rats, bFGF IR was only weakly expressed and co-localized with the microglial cell marker Iba1; however, 1 day after SpNL surgery, bFGF IR was strongly expressed and highly co-localized with Iba1 IR. In addition, injection of antibFGF antibody attenuated allodynia development. Elevation of bFGF expression in microglia has been reported in rat models of CNS injury and autoimmune encephalomyelitis. 14, 15 In the model of CNS injury, bFGF mRNA was detected in microglial cells in the brain 4 hours after cortical brain injury. 15 Notably, bFGF mRNA expression was strongly correlated with demyelination and was confined to neurons in normal tissue, but shifted to microglia upon nerve injury, paralleling the activation of microglial in response to EAE.
14 These findings, taken together with our present results, suggest that bFGF released from microglia during the early phase of nerve injury might contribute to the development of allodynia, and that bFGF released from astrocytes during later phases is associated with the maintenance of allodynia.
Activated microglial cells express several specific markers 16 and release inflammatory cytokines 7 or oxidizing radicals, or both. 17 Production of these factors can recruit other microglia, thereby promoting sensitization of the CNS. To investigate the mechanism underlying the inhibition of allodynia by the neutralization of bFGF, here, we investigated the immunolocalization and expression of several activated microglial-related factors. The microglialrelated markers Iba1, and the IR of the microglial-related inflammatory cytokines IL6 and TNFa increased in response to SpNL. We also found that neutralization of bFGF had no detectable effects on the gene expression of these markers; however, MPO IR markedly increased and co-localized with Iba1 IR during allodynia, and the expression of MPO was significantly decreased by the neutralization of bFGF. Reactive oxygen species have been implicated in the development of persistent pain states that result from nerve injury. 18 MPO is an oxidant-generating enzyme 19, 20 and promotes oxidative damage, which contributes to neuronal damage in the brain. 21 Although MPO is not typically expressed in healthy brain tissue, microglia in the brains of patients with neurodegenerative diseases are typically positive for MPO. 22 A recent study has also indicated that bFGF mediates redox activation in several cell types. 23 Together, these findings suggest that the neutralization of bFGF inhibits the progression of allodynia by suppressing the production of MPO in activated microglia.
Limitations of this study warrant mention. First, although several methods for the evaluation of mechanical allodynia have been reported, only the von Frey method was used in the present study. Second, due to the relatively small sample size, the statistical power of the analyses was low. Therefore, further studies are warranted to confirm these findings.
In conclusion, the present findings demonstrate that bFGF is rapidly increased in spinal microglia during allodynia after SpNL. The neutralization of bFGF attenuates allodynia development, possibly through the suppression of MPO production by spinal microglia. Controlling the expression of bFGF by microglia in the early stage after peripheral nerve injury might suppress the progression of pain; however, because bFGF neutralization did not completely suppress allodynia development, the identification of other factors for the regulation microglial activation is needed for developing effective treatment options for allodynia in the clinical setting.
